Toward Proteomic Precision Medicine for Steatotic Liver Diseases.
作者信息
Jakhar Niharika, Schneider Carolin V
机构信息
Medical Clinic III, Gastroenterology, Metabolic Diseases and Intensive Care University Hospital RWTH Aachen Aachen Germany.
出版信息
J Am Heart Assoc. 2025 May 20;14(10):e042254. doi: 10.1161/JAHA.125.042254. Epub 2025 May 15.
Abstract
摘要
相似文献
1
Toward Proteomic Precision Medicine for Steatotic Liver Diseases.迈向脂肪性肝病的蛋白质组学精准医学
J Am Heart Assoc. 2025 May 20;14(10):e042254. doi: 10.1161/JAHA.125.042254. Epub 2025 May 15.
2
Proteomic variation underlies the heterogeneous risk of metabolic dysfunction-associated steatotic liver disease for subsequent chronic diseases.蛋白质组学变异是代谢功能障碍相关脂肪性肝病发展为后续慢性疾病的异质性风险的基础。
Eur J Endocrinol. 2025 Apr 30;192(5):691-703. doi: 10.1093/ejendo/lvaf103.
3
Integrated multi-omic analysis identifies fatty acid binding protein 4 as a biomarker and therapeutic target of ischemia-reperfusion injury in steatotic liver transplantation.综合多组学分析鉴定脂肪酸结合蛋白 4 为肝脂肪变性移植肝缺血再灌注损伤的生物标志物和治疗靶点。
Cell Mol Life Sci. 2024 Feb 10;81(1):83. doi: 10.1007/s00018-023-05110-1.
4
ERp57 is up-regulated in free fatty acids-induced steatotic L-02 cells and human nonalcoholic fatty livers.内质网蛋白 57 在游离脂肪酸诱导的脂肪变性 L-02 细胞和人非酒精性脂肪肝中上调。
J Cell Biochem. 2010 Aug 15;110(6):1447-56. doi: 10.1002/jcb.22696.
5
[Proteomic-driven precision medicine research in hepatocellular carcinoma].[蛋白质组学驱动的肝细胞癌精准医学研究]
Zhonghua Gan Zang Bing Za Zhi. 2022 Aug 20;30(8):797-802. doi: 10.3760/cma.j.cn501113-20220616-00328.
6
MRI proton density fat fraction for estimation of tumor grade in steatotic hepatocellular carcinoma.磁共振质子密度脂肪分数在评估脂肪变性肝细胞癌肿瘤分级中的应用。
Eur Radiol. 2023 Dec;33(12):8974-8985. doi: 10.1007/s00330-023-09864-x. Epub 2023 Jun 27.
7
Driving Precision Medicine through Proteomics and Metabolomics - 12th Central and Eastern European Proteomic Conference (CEEPC), Bucharest, Romania.通过蛋白质组学和代谢组学推动精准医学发展-第 12 届中东欧蛋白质组学会议（CEEPC），罗马尼亚，布加勒斯特。
Expert Rev Proteomics. 2019 Jul;16(7):549-552. doi: 10.1080/14789450.2019.1630276. Epub 2019 Jun 17.
8
Uncovering hepatic transcriptomic and circulating proteomic signatures in MASH: A meta-analysis and machine learning-based biomarker discovery.揭示非酒精性脂肪性肝炎中的肝脏转录组学和循环蛋白质组学特征：一项荟萃分析和基于机器学习的生物标志物发现
Comput Biol Med. 2025 Jun;191:110170. doi: 10.1016/j.compbiomed.2025.110170. Epub 2025 Apr 12.
9
The hepatocellular model of fatty liver disease: from current imaging diagnostics to innovative proteomics technologies.脂肪肝疾病的肝细胞模型：从当前的影像诊断到创新的蛋白质组学技术
Front Med (Lausanne). 2025 Mar 5;12:1513598. doi: 10.3389/fmed.2025.1513598. eCollection 2025.
10
Metabolic dysfunction-associated steatotic liver disease and malignancies: Unmasking a silent saboteur.代谢功能障碍相关脂肪性肝病与恶性肿瘤：揭开沉默破坏者的面纱
Metabolism. 2025 Jul;168:156253. doi: 10.1016/j.metabol.2025.156253. Epub 2025 Mar 29.
本文引用的文献
1
Circulating Proteomics Identifies a Dynamic Profile of Hepatic Steatosis During Metabolic Intervention.循环蛋白质组学揭示了代谢干预期间肝脂肪变性的动态变化特征。
J Am Heart Assoc. 2025 May 20;14(10):e037100. doi: 10.1161/JAHA.124.037100. Epub 2025 May 15.
2
Deep proteome profiling of metabolic dysfunction-associated steatotic liver disease.代谢功能障碍相关脂肪性肝病的深度蛋白质组分析
Commun Med (Lond). 2025 Mar 3;5(1):56. doi: 10.1038/s43856-025-00780-3.
3
Molecular Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Transcriptome Analysis.基于转录组分析的代谢功能障碍相关脂肪性肝病的分子聚类
Diagnostics (Basel). 2025 Jan 31;15(3):342. doi: 10.3390/diagnostics15030342.
4
The Lipidomic Profile Discriminates Between MASLD and MetALD.脂质组学特征可区分代谢相关脂肪性肝病（MASLD）和代谢相关酒精性肝病（MetALD）。
Aliment Pharmacol Ther. 2025 Apr;61(8):1357-1371. doi: 10.1111/apt.70012. Epub 2025 Feb 11.
5
CCL16 is a pro-tumor chemokine that recruits monocytes and macrophages to promote hepatocellular carcinoma progression.CCL16是一种促肿瘤趋化因子，可募集单核细胞和巨噬细胞以促进肝细胞癌进展。
Am J Cancer Res. 2024 Jul 15;14(7):3600-3613. doi: 10.62347/VCTW6889. eCollection 2024.
6
Chemerin regulates glucose and lipid metabolism by changing mitochondrial structure and function associated with androgen/androgen receptor.Chemerin 通过改变与雄激素/雄激素受体相关的线粒体结构和功能来调节葡萄糖和脂质代谢。
Am J Physiol Endocrinol Metab. 2024 Jun 1;326(6):E869-E887. doi: 10.1152/ajpendo.00104.2023. Epub 2024 May 22.
7
Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population.普通人群中风险 MASH、MetALD 和酒精相关脂肪性肝病的流行情况。
Aliment Pharmacol Ther. 2024 May;59(10):1271-1281. doi: 10.1111/apt.17958. Epub 2024 Mar 19.
8
Clinical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis.多发性硬化症疾病活动评估的基于多种蛋白质的血清检测的临床验证。
Clin Immunol. 2023 Aug;253:109688. doi: 10.1016/j.clim.2023.109688. Epub 2023 Jul 4.
9
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.多学会专家共识：新的非酒精性脂肪性肝病命名。
Hepatology. 2023 Dec 1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520. Epub 2023 Jun 24.
10
CSF proteome profiling across the Alzheimer's disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels.在阿尔茨海默病谱中进行脑脊液蛋白质组谱分析反映了疾病的多因素性质，并确定了特定的生物标志物组合。
Nat Aging. 2022 Nov;2(11):1040-1053. doi: 10.1038/s43587-022-00300-1. Epub 2022 Nov 10.
Zotero 插件